In March 2023, we posted about a potential new therapy to treat hypoparathyroidism from Ascendis Pharma. Click here to read the earlier post.
Today, we update you that the U.S. Food and Drug Administration did not approve TransCon™ PTH just yet, but all hope is not lost. While the FDA is requiring additional information about the company’s manufacturing control strategy, it did not express concerns about the clinical data that Ascendis Pharma submitted and no new preclinical studies are required.
Click here to learn more.